223 related articles for article (PubMed ID: 33797740)
21. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
22. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Shouse G; Danilova OV; Danilov AV
Curr Opin Oncol; 2022 Sep; 34(5):540-545. PubMed ID: 35855508
[TBL] [Abstract][Full Text] [Related]
23. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
24. Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS/MS Method.
Weng Q; Lan X; Wang Y; Fan C; Xu RA; Zhang P
Front Pharmacol; 2022; 13():749095. PubMed ID: 35126158
[TBL] [Abstract][Full Text] [Related]
25. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
26. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
27. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
28. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Deng C; Lipstein MR; Scotto L; Jirau Serrano XO; Mangone MA; Li S; Vendome J; Hao Y; Xu X; Deng SX; Realubit RB; Tatonetti NP; Karan C; Lentzsch S; Fruman DA; Honig B; Landry DW; O'Connor OA
Blood; 2017 Jan; 129(1):88-99. PubMed ID: 27784673
[TBL] [Abstract][Full Text] [Related]
29. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Olszewski AJ; Shafqat H; Ali S
Leuk Lymphoma; 2015 Apr; 56(4):942-50. PubMed ID: 24956144
[TBL] [Abstract][Full Text] [Related]
30. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
31. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Armitage JO; Tobinai K; Hoelzer D; Rummel MJ
Int J Hematol; 2004 May; 79(4):311-21. PubMed ID: 15218957
[TBL] [Abstract][Full Text] [Related]
32. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
33. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
[TBL] [Abstract][Full Text] [Related]
34. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax: First Global Approval.
Deeks ED
Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
[TBL] [Abstract][Full Text] [Related]
36. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib: first global approval.
Cameron F; Sanford M
Drugs; 2014 Feb; 74(2):263-71. PubMed ID: 24464309
[TBL] [Abstract][Full Text] [Related]
38. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]